Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total value of $3,934,723.80. Following the completion of the sale, the director owned 35,600 shares in the company, valued at $1,712,004. This represents a 69.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Septerna Trading Up 1.8%

SEPN traded up $0.74 during mid-day trading on Friday, hitting $42.60. 337,791 shares of the stock were exchanged, compared to its average volume of 421,986. The firm’s fifty day moving average is $40.46 and its two-hundred day moving average is $33.12. Septerna, Inc. has a 1-year low of $19.69 and a 1-year high of $53.34. The company has a market cap of $2.03 billion, a PE ratio of -33.02 and a beta of 2.20.

Septerna (NASDAQ:SEPN – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The firm had revenue of $18.88 million for the quarter, compared to analysts’ expectations of $20.78 million. Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. As a group, research analysts anticipate that Septerna, Inc. will post -1.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SEPN. TRV GP V LLC purchased a new stake in shares of Septerna during the second quarter worth approximately $208,160,143. TRV GP VI LLC acquired a new stake in Septerna in the second quarter valued at approximately $141,048,460. BlackRock Inc. acquired a new stake in Septerna in the second quarter valued at approximately $64,706,000. Jupiter Topco LLC acquired a new stake in Septerna in the second quarter valued at approximately $43,723,000. Finally, Primecap Management Co. CA purchased a new position in Septerna in the second quarter worth approximately $39,096,000.

Top Septerna Stories

These are some of the SEPN stories that stood out recently:

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SEPN shares. Guggenheim raised their price objective on shares of Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Thursday, October 15th. JonesTrading upped their target price on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.44.

Get Our Latest Research Report on Septerna

About Septerna

(Get Free Report)

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Read More

Insider Buying and Selling by Quarter for Septerna (NASDAQ:SEPN)

Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.